Study S001011

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06373146
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 392
Start: 2024-04-24
Primary completion: 2025-12-15
Lead sponsor: Eli Lilly and Company
Conditions: Obesity
Interventions: DRUG:Tirzepatide; DRUG:Mibavademab; DRUG:Tirzepatide-Placebo; DRUG:Mibavademab-Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPIV

Registered primary outcomes

Mean Percent Change from Baseline in Body Weight [Baseline, Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.